Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
| Autor: | Craig B. Reeder, Jacy Spong, Christine Chen, V H J Zepeda, Suzanne Trudel, Vishal Kukreti, R Fonseca, Joseph R. Mikhael, Brie N. Noble, Nicholas A. Pirooz, Jesus Giovanni Piza, Alexander Keith Stewart, Jose F. Leis, Donna E. Reece, P L Bergsagel, Joseph G. Hentz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Cyclophosphamide medicine.drug_class Gastroenterology Article Dexamethasone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Multiple myeloma Aged Very Good Partial Response business.industry Bortezomib bortezomib clinical trial Hematology Middle Aged medicine.disease Boronic Acids Surgery Transplantation myeloma Treatment Outcome Oncology Pyrazines Proteasome inhibitor Corticosteroid cyclophosphamide Female business Multiple Myeloma medicine.drug Stem Cell Transplantation |
| Zdroj: | Leukemia |
| ISSN: | 1476-5551 0887-6924 |
| Popis: | We have studied a three-drug combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed multiple myeloma (MM) patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m(2) orally on days 1, 8, 15 and 22 and dexamethasone 40 mg orally on days 1-4, 9-12 and 17-20 on a 28-day cycle for four cycles. Responses were rapid with a mean 80% decline in the sentinel monoclonal protein at the end of two cycles. The overall intent to treat response rate (or= partial response) was 88%, with 61% of very good partial response or better (or=VGPR) and 39% of complete/near complete response (CR/nCR). For the 28 patients who completed all four cycles of therapy, the CR/nCR rate was 46% and VGPR rate was 71%. All patients undergoing stem cell harvest had a successful collection. Twenty-three patients underwent stem cell transplantation (SCT) and are evaluable through day 100 with CR/nCR documented in 70% andor=VGPR in 74%. In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed MM with manageable toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|